Terms: = Brain cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
83 results:
1. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract] [Full Text] [Related]
2. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
3. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
4. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
5. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
6. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.
Cheng S; Han Z; Dai D; Li F; Zhang X; Lu M; Lu Z; Wang X; Zhou J; Li J; Guo X; Song P; Qiu C; Shen W; Zhang Q; Zhu N; Wang X; Tan Y; Kou Y; Yin X; Shen L; Peng Z
Cell Rep Med; 2024 Jan; 5(1):101355. PubMed ID: 38194971
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract] [Full Text] [Related]
8. Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
Lu S; Guo X; Li Y; Liu H; Zhang Y; Zhu H
Cancer; 2024 Jan; 130(1):18-30. PubMed ID: 37682730
[TBL] [Abstract] [Full Text] [Related]
9. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.
Yan X; Qu F; Zhou Y
Lung Cancer; 2023 Oct; 184():107322. PubMed ID: 37611495
[TBL] [Abstract] [Full Text] [Related]
10. Effect of whole-brain radiotherapy with platinum-based chemotherapy in non-small cell lung cancer patients with multiple metastases including brain metastases.
Ryu WK; Cha HK; Kim W; Lee HY; Kim HJ; Ryu JS; Lim JH
Sci Rep; 2023 Aug; 13(1):13173. PubMed ID: 37580499
[TBL] [Abstract] [Full Text] [Related]
11. Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung cancer Patients: A Retrospective Study.
Blasi M; Kuon J; Shah R; Bozorgmehr F; Eichhorn F; Liersch S; Stenzinger A; Heußel CP; Herth FJ; Thomas M; Christopoulos P
Clin Lung Cancer; 2023 Nov; 24(7):e282-e290. PubMed ID: 37391339
[TBL] [Abstract] [Full Text] [Related]
12. pdl1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors.
Lasvergnas J; Fallet V; Duchemann B; Jouveshomme S; Cadranel J; Chouaïd C
Respir Med Res; 2023 Nov; 84():101018. PubMed ID: 37302160
[TBL] [Abstract] [Full Text] [Related]
13. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Aug; 28(8):941-955. PubMed ID: 37300720
[TBL] [Abstract] [Full Text] [Related]
14. Integrative Oncology's 30-Year Anniversary: What Have We Achieved? A North American Naturopathic Oncology Perspective.
Standish LJ; Malani SM; Lynch K; Whinkin EJ; McCotter CM; Lynch DA; Aggarwal SK
Integr Cancer Ther; 2023; 22():15347354231178911. PubMed ID: 37294048
[TBL] [Abstract] [Full Text] [Related]
15. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
Duerinck J; Tuyaerts S; Movahedi K; Neyns B
Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
[TBL] [Abstract] [Full Text] [Related]
16. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
Garcia D; Mambetsariev I; Fricke J; Schmolze D; Afkhami M; Mannan R; Kim P; Therese Dingal S; Nguyen B; Babikian R; Fong Y; Salgia R
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37160318
[TBL] [Abstract] [Full Text] [Related]
17. Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis.
Hoffmann E; De-Colle C; Potkrajcic V; Baumann D; Spengler W; Gani C; Utz D
Strahlenther Onkol; 2023 Jul; 199(7):668-675. PubMed ID: 37039832
[TBL] [Abstract] [Full Text] [Related]
18. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract] [Full Text] [Related]
19. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract] [Full Text] [Related]
20. brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H
Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899
[TBL] [Abstract] [Full Text] [Related]
[Next]
